Docosahexaenoic Acid Downregulates EGF-Induced Urokinase Plasminogen Activator and Matrix Metalloproteinase 9 Expression by Inactivating EGFR/ErbB2 Signaling in SK-BR3 Breast Cancer Cells

REFERENCES

• Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al.: Global cancer statistics. CA Cancer J Clin 61, 69–90, 2011.
   PubMed Web of Science ®Google Scholar
• Kao J, Salari K, Bocanegra M, Choi YL, Girard L, et al.: Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One 4, e6146, 2009.
   PubMed Web of Science ®Google Scholar
• Hynes NE and Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5, 341–354, 2005.
   PubMed Web of Science ®Google Scholar
• Graus-Porta D, Beerli RR, Daly JM, and Hynes NE: ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16, 1647–1655, 1997.
   PubMed Web of Science ®Google Scholar
• Olayioye MA, Neve RM, Lane HA, and Hynes NE: The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19, 3159–3167, 2000.
   PubMed Web of Science ®Google Scholar
• Cortés MA, Cariaga-Martinez AE, Lobo MV, Martín Orozco RM, Motiño O, et al.: EGF promotes neuroendocrine-like differentiation of prostate cancer cells in the presence of LY294002 through increased ErbB2 expression independent of the phosphatidylinositol 3-kinase-AKT pathway. Carcinogenesis 33, 1169–1177, 2012.
   PubMed Web of Science ®Google Scholar
• Gupta P and Srivastava SK: Antitumor activity of phenethylisothiocyanate in HER2-positive breast cancer models. BMC Med 10, 80, 2012.
   PubMed Web of Science ®Google Scholar
• Magkou C, Nakopoulou L, Zoubouli C, Karali K, Theohari I, et al.: Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas. Breast Cancer Res 10, R49, 2008.
   PubMed Web of Science ®Google Scholar
• Afsharimani B, Baran J, Watanabe S, Lindner D, Cabot PJ, et al.: Morphine and breast tumor metastasis: the role of matrix-degrading enzymes. Clin Exp Metastasis 31, 149–158, 2013.
   PubMed Web of Science ®Google Scholar
• Annecke K, Schmitt M, Euler U, Zerm M, Paepke D, et al.: uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial. Adv Clin Chem 45, 31–45, 2008.
   PubMed Web of Science ®Google Scholar
• Sung H, Choi JY, Lee SA, Lee KM, Han S, et al.: The association between the preoperative serum levels of lipocalin-2 and matrix metalloproteinase-9 (MMP-9) and prognosis of breast cancer. BMC Cancer 12, 193, 2012.
   Web of Science ®Google Scholar
• Bax NA, van Marion MH, Shah B, Goumans MJ, Bouten, CV, et al.: Matrix production and remodeling capacity of cardiomyocyte progenitor cells during in vitro differentiation. J Mol Cell Cardiol 53, 497–508, 2012.
   PubMed Web of Science ®Google Scholar
• Gialeli C, Theocharis AD, and Karamanos NK: Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 278, 16–27, 2011.
   PubMed Web of Science ®Google Scholar
• Vempati P, Karagiannis ED, and Popel AS: A biochemical model of matrix metalloproteinase 9 activation and inhibition. J Biol Chem 282, 37585–37596, 2007.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Lyons CE Jr, Xiao A, Templeton DJ, Sang QA, et al.: Urokinase directly activates matrixmetalloproteinases-9: a potential role in glioblastoma invasion. Biochem Biophys Res Commun 369, 1215–1220, 2008.
   PubMed Web of Science ®Google Scholar
• Benasciutti E, Pagès G, Kenzior O, Folk W, Blasi F, et al.: MAPK and JNK transduction pathways can phosphorylate Sp1 to activate the uPA minimal promoter element and endogenous gene transcription. Blood 104, 256–262, 2004.
   PubMed Web of Science ®Google Scholar
• Chen HW, Chao CY, Lin LL, Lu CY, Liu KL, et al.: Inhibition of matrix metalloproteinase-9 expression by docosahexaenoic acid mediated by hemeoxygenase 1 in 12-O-tetradecanoylphorbol-13-acetate-induced MCF-7 human breast cancer cells. Arch Toxicol 87, 857–869, 2013.
   PubMed Web of Science ®Google Scholar
• Hwang YP, Yun HJ, Choi JH, Han EH, Kim HG, et al.: Suppression of EGF-induced tumor cell migration and matrix metalloproteinase-9 expression by capsaicin via the inhibition of EGFR-mediated FAK/Akt, PKC/Raf/ERK, P38 MAPK, and AP-1 signaling. Mol Nutr Food Res 55, 594–605, 2011.
   PubMed Web of Science ®Google Scholar
• Horrocks LA and Yeo YK: Health benefits of docosahexaenoic acid (DHA). Pharmacol Res 40, 211–225, 1999.
   PubMed Web of Science ®Google Scholar
• Bougnoux P, Hajjaji N, Ferrasson MN, Giraudeau B, Couet C, et al.: Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoicacid: a phase II trial. Br J Cancer 101, 1978–1985, 2009.
   PubMed Web of Science ®Google Scholar
• Spencer L, Mann C, Metcalfe M, Webb M, Pollard C, et al.: The effect of omega-3 FAs on tumour angiogenesis and their therapeutic potential. Eur J Cancer 45, 2077–2086, 2009.
   PubMed Web of Science ®Google Scholar
• Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680–685, 1970.
   PubMed Web of Science ®Google Scholar
• Yang YC, Lii CK, Wei YL, Li CC, Lu CY, et al.: Docosahexaenoic acid inhibition of inflammation is partially via cross-talk between Nrf2/hemeoxygenase 1 and IKK/NF-κB pathways. J Nutr Biochem 24, 204–212, 2013.
   PubMed Web of Science ®Google Scholar
• Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2−△△cT method. Methods 25, 402–408, 2001.
   PubMed Web of Science ®Google Scholar
• Chou RH, Hsieh SC, Yu YL, Huang MH, Huang YC, et al.: Fisetin inhibits migration and invasion of human cervical cancer cells by down-regulating urokinase plasminogen activator expression through suppressing the p38 MAPK-dependent NF-κB signaling pathway. PLoS One 8, e71983, 2013.
   PubMed Web of Science ®Google Scholar
• Chao CY, Lii CK, Hsu YT, Lu CY, Liu KL, et al.: Induction of heme oxygenase-1 and inhibition of TPA-induced matrix metalloproteinase-9 expression by andrographolide in MCF-7 human breast cancer cells. Carcinogenesis 34, 1843–1851, 2013.
   PubMed Web of Science ®Google Scholar
• Watabe T, Yoshida K, Shindoh M, Kaya M, Fujikawa K, et al.: The Ets-1 and Ets-2 transcription factors activate the promoters for invasion-associated urokinase and collagenase genes in response to epidermal growth factor. Int J Cancer 137, 128–137, 1998.
   Web of Science ®Google Scholar
• Kim S, Choi JH, Lim HI, Lee SK, Kim WW, et al.: EGF-induced MMP-9 expression is mediated by the JAK3/ERK pathway, but not by the JAK3/STAT-3pathway in a SKBR3 breast cancer cell line. Cell Signal 21, 892–898, 2009.
   PubMed Web of Science ®Google Scholar
• Anteby EY, Greenfield C, Natanson-Yaron S, Goldman-Wohl D, Hamani Y, et al.: Vascular endothelial growth factor, epidermal growth factor and fibroblast growth factor-4 and -10 stimulate trophoblast plasminogen activator system and metalloproteinase-9 . Mol Hum Reprod 10, 229–235, 2004.
   PubMed Web of Science ®Google Scholar
• Mannello F and Ligi D: Resolving breast cancer heterogeneity by searching reliable protein cancer biomarkers in the breast fluid secretome. BMC Cancer 13, 344, 2013.
   PubMed Web of Science ®Google Scholar
• Wilkins-Port CE, Higgins SP, Higgins CE, Kobori-Hotchkiss I, and Higgins PJ: Complex regulation of the pericellular proteolytic microenvironment during tumor progression and wound repair: Functional interactions between the serine protease and matrix metalloproteinase cascades. Biochem Res Int 2012, 454368, 2012.
   PubMedGoogle Scholar
• Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, et al.: The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 1, 84–96, 2007.
   PubMed Web of Science ®Google Scholar
• Wolff C, Malinowsky K, Berg D, Schragner K, Schuster T, et al.: Signaling networks associated with urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in breast cancer tissues: new insights from protein microarray analysis. J Pathol 223, 54–63, 2011.
   PubMed Web of Science ®Google Scholar
• Zhang YG, Du Q, Fang WG, Jin ML, and Tian XX: Tyrphostin AG1478 suppresses proliferation and invasion of human breast cancer cells. Int J Oncol 33, 595–602, 2008.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Angulo AM, Hennessy BT, Meric-Bernstam F, Sahin A, Liu W, et al.: Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clin Proteomics 8, 11–25, 2011.
   PubMedGoogle Scholar
• Milanezi F, Carvalho S, and Schmitt FC: EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy. Expert Rev Mol Diagn 8, 417–434, 2008.
   PubMed Web of Science ®Google Scholar
• Rogers KR, Kikawa KD, Mouradian M, Hernandez K, McKinnon KM, et al.: Docosahexaenoic acid alters epidermal growth factor receptor-related signaling by disrupting its lipid raft association. Carcinogenesis 31, 1523–1530, 2010.
   PubMed Web of Science ®Google Scholar
• Turk HF, Barhoumi R, and Chapkin RS: Alteration of EGFR spatiotemporal dynamics suppresses signal transduction. PLoS One 7, e39682, 2012.
   PubMed Web of Science ®Google Scholar
• Lee EJ, Yun UJ, Koo KH, Sung JY, Shim J, et al.: Down-regulation of lipid raft-associated onco-proteins via cholesterol-dependent lipid raft internalization in docosahexaenoic acid-induced apoptosis. Biochim Biophys Acta 1841, 190–203, 2014.
   PubMed Web of Science ®Google Scholar
• Corsetto PA, Montorfano G, Zava S, Jovenitti IE, Cremona A, et al.: Effects of n-3 PUFAs on breast cancer cells through their incorporation in plasma membrane. Lipids Health Dis 10, 73, 2011.
   PubMed Web of Science ®Google Scholar
• Anido J, Matar P, Albanell J, Guzmán M, Rojo F, et al.: ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res 9, 1274–1283, 2003.
   PubMed Web of Science ®Google Scholar
• Kong A, Calleja V, Leboucher P, Harris A, Parker PJ, et al.: HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells. PLoS One 3, e2881, 2008.
   PubMed Web of Science ®Google Scholar
• Moasser MM, Basso A, Averbuch SD, and Rosen N: The tyrosine kinase inhibitor ZD1839 (‘′Iressa′’) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 61, 7184–7188, 2001.
   PubMed Web of Science ®Google Scholar
• Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, et al.: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369, 29–36, 2007.
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, et al.: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687–697, 2010.
   PubMed Web of Science ®Google Scholar
• Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, et al.: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355, 2733–2743, 2006.
   PubMed Web of Science ®Google Scholar
• Blok EJ, Kuppen PJ, van Leeuwen JE, and Sier CF: Cytoplasmic Overexpression of HER2: a Key Factor in Colorectal Cancer. Clin Med Insights Oncol 7, 41–51, 2013.
   PubMedGoogle Scholar